HK1127489A1 - Pyridiazinone derivatives for the treatment of tumours - Google Patents

Pyridiazinone derivatives for the treatment of tumours

Info

Publication number
HK1127489A1
HK1127489A1 HK09105156.0A HK09105156A HK1127489A1 HK 1127489 A1 HK1127489 A1 HK 1127489A1 HK 09105156 A HK09105156 A HK 09105156A HK 1127489 A1 HK1127489 A1 HK 1127489A1
Authority
HK
Hong Kong
Prior art keywords
pyridiazinone
tumours
derivatives
treatment
pyridiazinone derivatives
Prior art date
Application number
HK09105156.0A
Other languages
English (en)
Inventor
Dieter Dorsch
Oliver Schadt
Andree Blaukat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1127489A1 publication Critical patent/HK1127489A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK09105156.0A 2005-12-05 2009-06-09 Pyridiazinone derivatives for the treatment of tumours HK1127489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005057924A DE102005057924A1 (de) 2005-12-05 2005-12-05 Pyridazinonderivate
PCT/EP2006/010668 WO2007065518A1 (fr) 2005-12-05 2006-11-07 Derive de pyridiazinone pour le traitement de tumeurs

Publications (1)

Publication Number Publication Date
HK1127489A1 true HK1127489A1 (en) 2009-09-25

Family

ID=37775213

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105156.0A HK1127489A1 (en) 2005-12-05 2009-06-09 Pyridiazinone derivatives for the treatment of tumours

Country Status (28)

Country Link
US (1) US8173653B2 (fr)
EP (1) EP1960370B1 (fr)
JP (1) JP5210172B2 (fr)
KR (1) KR101367447B1 (fr)
CN (1) CN101326167B (fr)
AR (1) AR057214A1 (fr)
AT (1) ATE527241T1 (fr)
AU (1) AU2006322364B2 (fr)
BR (1) BRPI0619407A2 (fr)
CA (1) CA2632217C (fr)
CY (1) CY1112206T1 (fr)
DE (1) DE102005057924A1 (fr)
DK (1) DK1960370T3 (fr)
EA (1) EA014667B1 (fr)
EC (1) ECSP088598A (fr)
ES (1) ES2373117T3 (fr)
HK (1) HK1127489A1 (fr)
IL (1) IL191832A (fr)
MY (1) MY153261A (fr)
NZ (1) NZ569568A (fr)
PE (1) PE20070832A1 (fr)
PL (1) PL1960370T3 (fr)
PT (1) PT1960370E (fr)
SI (1) SI1960370T1 (fr)
TW (1) TWI395741B (fr)
UA (1) UA95934C2 (fr)
WO (1) WO2007065518A1 (fr)
ZA (1) ZA200805877B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574873A (en) 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
CN101636386A (zh) * 2006-12-14 2010-01-27 安斯泰来制药有限公司 用作crth2拮抗剂和抗过敏剂的多环酸化合物
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
MY160526A (en) * 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
EA019342B1 (ru) * 2009-01-08 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы гидрохлоридной соли 3-(1-{3-[5-(1-метилпиперидин-4-илметокси)пиримидин-2-ил]бензил}-6-оксо-1,6-дигидропиридазин-3-ил)бензонитрила и способы их получения
CN102731409A (zh) * 2011-04-08 2012-10-17 中国科学院上海药物研究所 一类哒嗪酮类化合物,其药物组合物、制备方法及用途
KR101842645B1 (ko) 2012-04-12 2018-03-29 한국화학연구원 신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도
ES2646913T3 (es) * 2012-11-02 2017-12-18 Merck Patent Gmbh Un derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento del carcinoma hepatocelular (HCC)
PL3640241T3 (pl) 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
CN103772352B (zh) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
CA2970394C (fr) * 2014-12-11 2023-03-14 Merck Patent Gmbh Association d'un derive de 6-oxo-1,6-dihydro-pyridazine ayant une activite anticancereuse avec un derive de quinazoline
WO2018081381A1 (fr) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc Composés de pyridazine, compositions et méthodes permettant de moduler cftr
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2019043217A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
WO2020097258A1 (fr) * 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Composés de pyridazinone et leurs utilisations
HUE063586T2 (hu) 2018-11-06 2024-01-28 Edgewise Therapeutics Inc Piridazinon-vegyületek és alkalmazásaik
KR20210100615A (ko) 2018-11-06 2021-08-17 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
EP3935050B1 (fr) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO79566A2 (fr) * 1980-05-28 1982-08-17 Institutul De Cercetari Chimico-Farmaceutice,Ro Substances de la classe 2-(3'-aryle-pyridazonyle-1'5-methyle-5-aryle-(alkyle) amino-thiadiazole
RO79562A2 (fr) * 1980-05-29 1982-08-17 Institutul De Cercetari Chimico-Farmaceutice,Ro Substances de la classe 3-(3'-aryle-pyridazonyle-1'5-methyle-4-aryle(alkyle)-5-mercapthio-1,2,4-triazole et procede d'obtention
JPS5826802A (ja) * 1981-08-10 1983-02-17 Sankyo Co Ltd 農園芸用殺菌剤
DE3321012A1 (de) * 1983-06-10 1984-12-13 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
ATE180475T1 (de) * 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
IE913310A1 (en) * 1990-09-21 1992-02-25 Rohm & Haas Dihydropyridazinones, pyridazinones and related compounds as¹fungicides
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
CA2216512A1 (fr) * 1996-10-11 1998-04-11 Rohm And Haas Company Dihydropyridazinones et pyridazinones, leur utilisation comme fongicides et insecticides
WO1999010332A1 (fr) * 1997-08-22 1999-03-04 Abbott Laboratories Inhibiteurs de la biosynthese de la prostaglandine h2 synthetase
BR9813998A (pt) * 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
US7060822B1 (en) 1999-07-30 2006-06-13 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
KR20020091829A (ko) 1999-07-30 2002-12-06 애보트 게엠베하 운트 콤파니 카게 2-피라졸린-5-온
AUPR606401A0 (en) * 2001-07-02 2001-07-26 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
MXPA04003668A (es) * 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
EP1470112A1 (fr) * 2002-01-18 2004-10-27 Pharmacia Corporation Pyridazinones substituees inhibant la map kinase p38
US20040067955A1 (en) * 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
NZ541064A (en) * 2003-03-07 2007-09-28 Kowa Co Benzofuran derivative
KR20060028632A (ko) * 2003-04-25 2006-03-30 길리애드 사이언시즈, 인코포레이티드 항염증 포스포네이트 화합물
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7763617B2 (en) * 2005-03-07 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient

Also Published As

Publication number Publication date
AR057214A1 (es) 2007-11-21
IL191832A (en) 2013-09-30
PE20070832A1 (es) 2007-08-27
UA95934C2 (ru) 2011-09-26
CA2632217A1 (fr) 2007-06-14
JP2009518323A (ja) 2009-05-07
ZA200805877B (en) 2009-07-29
CN101326167B (zh) 2011-03-09
AU2006322364B2 (en) 2012-01-12
NZ569568A (en) 2011-05-27
KR20080077664A (ko) 2008-08-25
US20080293719A1 (en) 2008-11-27
MY153261A (en) 2015-01-29
DK1960370T3 (da) 2012-01-02
ATE527241T1 (de) 2011-10-15
PL1960370T3 (pl) 2012-01-31
TW200804303A (en) 2008-01-16
PT1960370E (pt) 2012-01-11
AU2006322364A1 (en) 2007-06-14
BRPI0619407A2 (pt) 2011-10-04
DE102005057924A1 (de) 2007-06-06
JP5210172B2 (ja) 2013-06-12
WO2007065518A1 (fr) 2007-06-14
TWI395741B (zh) 2013-05-11
EP1960370A1 (fr) 2008-08-27
EP1960370B1 (fr) 2011-10-05
CA2632217C (fr) 2014-07-08
ES2373117T3 (es) 2012-01-31
EA200801428A1 (ru) 2008-10-30
US8173653B2 (en) 2012-05-08
CN101326167A (zh) 2008-12-17
CY1112206T1 (el) 2015-12-09
EA014667B1 (ru) 2010-12-30
ECSP088598A (es) 2008-08-29
KR101367447B1 (ko) 2014-02-25
SI1960370T1 (sl) 2011-12-30
IL191832A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
IL188430A0 (en) Treatment of tumors
IL188746A0 (en) Treatment of cancer
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
HK1117780A1 (en) Compounds and methods for the treatment of cancer
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
GB0517387D0 (en) Combinations for the treatment of cancer
GB2443588B (en) A pharmaceutical composition useful for the treatment of prostate cancer
EP1904088A4 (fr) Compositions et methodes de traitement du cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0520067D0 (en) Treatment of cancer
IL226362A0 (en) compounds, and methods for treating cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0525535D0 (en) Tumour treatment
ZA200706871B (en) Treatment of metastasized tumors
GB0507685D0 (en) Cancer treatment
GB0517386D0 (en) Combinations for the treatment of cancer
GB0602857D0 (en) The treatment of sialorrhoea
GB0508411D0 (en) Treatment of tumours
GB0604114D0 (en) Combinations for the treatment of cancer
TJ20050863A (en) The way of narcotism treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201107